

Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2020

<https://marketpublishers.com/r/GEF4B2AF9E6EN.html>

Date: October 2020

Pages: 56

Price: US\$ 3,500.00 (Single User License)

ID: GEF4B2AF9E6EN

Abstracts

Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2020

SUMMARY

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2020, outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta-cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose-dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide. Glucose-dependent insulinotropic polypeptide is released from the duodenum and small intestine. GIP binds to GIPR through hydrophobic interactions and triggering activation of G protein-coupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogenous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to

bind properly to GIPR.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 4, 4, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Gastrointestinal, Cardiovascular and Musculoskeletal Disorders which include indications Obesity, Type 2 Diabetes, Alzheimer's Disease, Non-Alcoholic Steatohepatitis (NASH), Diabetes, Non Alcoholic Fatty Liver Disease (NAFLD), Parkinson's Disease, Cardiovascular Risk Factors, Circadian Rhythm Sleep Disorders, Osteoporosis, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Primary Sclerosing Cholangitis.

Furthermore, this report also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)

The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects

The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gastric

Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Overview

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development

Amgen Inc

Antag Therapeutics ApS

Bainan Biotech ApS

Carmot Therapeutics Inc

Eli Lilly and Co

Hanmi Pharmaceuticals Co Ltd

Kariya Pharmaceuticals IVS

Longevity Biotech Inc

Zealand Pharma AS

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles

AMG-133 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Agonize GLP-1R, GIPR and GLR for Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-868 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DAJC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-15211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBT-6030 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Antagonize GIPR for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GIPR and GLP1R for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide 1 for Type 2 Diabetes, Obesity and Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease and Type 1 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Agonize GIPR and GLP1R for Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize GIP, GR and GLP-1R for Gastrointestinal and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tirzepatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Products

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Product Development Milestones

Featured News & Press Releases

Jun 10, 2020: Lilly begins dosing in cardiovascular outcomes trial of tirzepatide

Mar 11, 2020: Hanmi's NASH treatment wins more orphan drug status

Feb 28, 2020: Hanmi's anti-NASH drug candidate set to become 'game changer' in global pharmaceutical market

Jun 08, 2019: Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Associations 79 Scientific Sessions

May 29, 2019: Lilly announces webcast to discuss on tirzepatide at the American Diabetes Association's 79th Scientific Sessions

Dec 19, 2018: Carmot Therapeutics initiates phase 1 trial to treat type 2 diabetes

Oct 05, 2018: Lilly reports positive results for GIP/GLP-1 RA in type 2 diabetes trial

Appendix

Methodology

Coverage

Secondary Research

[Primary Research](#)
[Expert Panel Validation](#)
[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indication, H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Number of Products under Investigation by Universities/Institutes, H2 2020

Products under Investigation by Universities/Institutes, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by Amgen Inc, H2 2020

Pipeline by Antag Therapeutics ApS, H2 2020

Pipeline by Bainan Biotech ApS, H2 2020

Pipeline by Carmot Therapeutics Inc, H2 2020

Pipeline by Eli Lilly and Co, H2 2020

Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2020

Pipeline by Kariya Pharmaceuticals IVS, H2 2020

Pipeline by Longevity Biotech Inc, H2 2020

Pipeline by Zealand Pharma AS, H2 2020

Dormant Products, H2 2020

Dormant Products, H2 2020 (Contd..1), H2 2020

Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

I would like to order

Product name: Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/GEF4B2AF9E6EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GEF4B2AF9E6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970